8:45am ET
Investing
Huge Insider Buying in MGM and Salesforce
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Companies
/Healthcare
DiaMedica Therapeutics Inc
$8.72
▲ $0.09 (+1.04%) today
Markets closed · 7:26am ET
DMAC at a Glance
Valuation
- Market cap
- $470.2M
Profitability
- EPS (TTM)
- $-0.72
Price
- 52-week range
- $5 – $10
- Street target
- $15.50
Earnings
- Next report
- Nov 11, 2026
Headquartered in Minneapolis, MN Fiscal year ends December NASDAQ: DMAC diamedica.com
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious ischemic diseases, with primary indications in preeclampsia, fetal growth restriction, and acute ischemic stroke. Its lead candidate, DM199, is a recombinant (synthetic) form of the KLK1 protein, a therapeutic modality used in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases. The company is conducting multiple clinical trials including the Phase 2/3 ReMEDy2 trial for acute ischemic stroke across the US, Canada, UK, and Europe, an investigator-sponsored Phase 2 trial in preeclampsia and fetal growth restriction in South Africa, and a newly authorized Phase 2 study in early-onset preeclampsia in Canada with planned expansion to the UK. DiaMedica generates no revenue and is funded through equity financing, with operations focused entirely on clinical development. Updated
Frequently Asked Questions
What does DiaMedica Therapeutics do?
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious ischemic diseases, with primary indications in preeclampsia, fetal growth restriction, and acute ischemic stroke.
What is the DMAC stock price target?
The Wall Street consensus 12-month price target for DMAC is $15.50.